Hegseth’s Testosterone Testing Plan Could Reshape Military Medicine, But the Hardest Questions Begin After the Blood Draw
Pete Hegseth’s new testosterone testing policy will screen troops aged 30 and older annually, raising major questions about diagnosis, fertility, deployment, privacy, women’s health and performance enhancement.
The Pentagon is preparing to turn a hormone measurement into a new marker of military readiness.
Defense Secretary Pete Hegseth announced that service members aged 30 and older will receive annual screening for testosterone deficiency as part of required medical assessments. Troops under 30 may request testing voluntarily, while testosterone replacement therapy will remain optional for those found to have a medically confirmed deficiency.
Hegseth described the initiative as an effort to keep American troops strong, resilient and capable of operating at their “absolute best.” He also insisted that the program is intended to restore natural function, not manufacture artificially enhanced fighters.
That distinction sounds straightforward in an announcement. Inside the military’s medical system, however, it could become extremely complicated.
We are not simply watching the Pentagon add another blood test to an annual physical. We are watching it attempt to separate legitimate hormone treatment from performance enhancement while managing fertility risks, irregular deployment schedules, medical privacy, and the possibility that troops could feel pressured to accept supposedly voluntary treatment.
The Pentagon Has Not Explained Why Testing Begins at 30
The policy’s first unanswered question is also one of its most important: Why did the Pentagon select age 30?
Testosterone levels can gradually decline with age, but a person’s 30th birthday does not create an automatic medical deficiency. Some healthy men maintain normal levels well beyond middle age, while younger men can develop low testosterone because of injury, medication, obesity, pituitary disorders, or other medical conditions.
The Endocrine Society generally recommends against routinely screening otherwise healthy men without symptoms. Its clinical guidance says hypogonadism should be diagnosed only when a patient has symptoms consistent with testosterone deficiency and repeatedly low hormone readings.
The Pentagon has not publicly released research showing that universal screening beginning at 30 will improve military performance, reduce injuries, or increase retention. It has also not disclosed the testosterone level that will trigger further evaluation.
That leaves a critical question hanging over the initiative: Was the age threshold chosen through military health data, or because 30 offers a simple administrative dividing line?
One Low Reading Should Not Become an Automatic Prescription
Testosterone is difficult to measure accurately because hormone levels fluctuate throughout the day.
Clinical guidelines recommend collecting blood early in the morning, when testosterone is usually highest. An abnormal result should generally be confirmed with a second fasting morning test on a different day. Doctors must also consider symptoms, medications, medical history, and possible underlying conditions before making a diagnosis.
That process may be routine in a civilian clinic. It becomes much harder in the military.
A service member may be tested after a night shift, a long flight, an intense training exercise, or weeks of disrupted sleep. Deployed troops may cross several time zones, work rotating schedules, or live under conditions that temporarily affect their bodies.
A single blood test taken after severe physical stress may not represent a troop’s normal hormone level. If the Pentagon wants medically reliable results, it must build repeat testing and clinical evaluation into the program.
The annual screening should therefore be treated as the beginning of an investigation, not the final diagnosis.
Low Testosterone May Be a Warning Sign, Not the Real Problem
Fatigue, reduced motivation, weight gain, poor concentration, and mood changes are often associated with low testosterone. They can also signal depression, sleep apnea, thyroid disease, medication side effects, chronic stress, or inadequate recovery.
These overlapping symptoms are especially important in military populations. Service members may endure irregular sleep, repeated deployments, traumatic injuries, demanding physical training, and long periods away from family.
If doctors respond to every abnormal testosterone result with hormone therapy, they may overlook a deeper medical or psychological problem.
Recent research presented at the Endocrine Society’s 2026 annual meeting illustrates the danger. In a review of men receiving initial testosterone prescriptions, only a small proportion had completed the full guideline-aligned diagnostic process before treatment. Common conditions among the patients included obesity, hypertension, and depression, all of which can complicate the clinical picture.
The Pentagon could avoid that problem by requiring military doctors to investigate the cause of a low hormone level before attempting to raise it.
Fertility Could Become the Policy’s Most Personal Consequence
The debate surrounding testosterone often focuses on strength, energy, and sexual function. Far less attention is given to fertility.
Testosterone replacement can suppress the body’s natural production of reproductive hormones and reduce sperm production. FDA-approved prescribing information warns that treatment can cause severely reduced sperm counts and possible infertility.
That risk could have life-changing consequences for younger troops who hope to start families.
A service member may accept treatment believing it will improve energy or physical performance without realizing that it could complicate future parenthood. The Pentagon will need to decide whether fertility counseling becomes mandatory before treatment and whether sperm preservation will be offered to patients planning long-term therapy.
A readiness initiative cannot be considered medically complete if troops learn about fertility risks only after treatment has begun.
“Voluntary” Treatment Could Still Carry Career Pressure
Hegseth has said hormone replacement therapy will be voluntary. Military culture, however, can make medical choices feel less voluntary than they appear on paper.
Service members are routinely evaluated on physical fitness, deployability, and their ability to complete demanding assignments. A troop that declines treatment may worry about being viewed as less committed, less capable, or unwilling to correct a potential readiness problem.
The Pentagon must clearly define who can access individual test results. Commanders may need to know whether a person is medically deployable, but they should not automatically receive detailed information about sexual symptoms, fertility concerns, or hormone measurements.
The policy should also prohibit commanders from pressuring troops to begin treatment or treating a refusal as a failure of discipline.
Without strong privacy rules, an intimate medical decision could become another unofficial career test.
The Military Must Draw a Firm Line Between Treatment and Enhancement
The Pentagon’s initiative creates an unusual contradiction.
The military will begin looking for troops who have too little testosterone while continuing to test for unauthorized testosterone-related substances used to increase muscle and performance.
Naval Special Warfare introduced random testing for performance-enhancing drugs after concerns about unauthorized substance use among elite personnel. Navy guidance states that steroid use is prohibited unless it has been prescribed by a qualified medical provider.
A prescription may establish the legal difference, but it does not answer every medical question.
The Pentagon will need limits governing dosage, target hormone levels, and frequency of treatment. It must ensure that replacement therapy restores a clinically normal range rather than pushing troops beyond it.
Otherwise, two service members could use similar substances for similar performance goals while only one faces disciplinary action.
The credibility of the policy will depend on whether military doctors, not commanders, influencers, or fitness culture, control the treatment decisions.
Blood Pressure Monitoring Cannot Be an Afterthought.
Public concern about testosterone therapy once focused heavily on heart attack and stroke risks.
In 2025, the FDA removed earlier boxed-warning language about major cardiovascular events after reviewing evidence from a large safety trial. At the same time, the agency required class-wide warnings because studies showed that testosterone products can increase blood pressure.
That matters in a military setting.
Troops may train in extreme heat, carry heavy equipment, and complete missions in locations where medical monitoring is limited. A treatment that raises blood pressure could require closer supervision among personnel already working under significant physical strain.
Military clinicians will need to monitor blood pressure, dosage, and side effects after treatment begins. Screening thousands of troops will accomplish little if the system cannot provide reliable follow-up care.
Deployment Could Turn Routine Treatment Into a Logistical Challenge
Testosterone replacement is not a one-time medical intervention.
Depending on the product, a patient may require scheduled injections, daily gels, repeat laboratory testing, and periodic dose adjustments. Maintaining that routine can be difficult aboard ships, at remote installations, or during combat deployments.
Gels may require careful handling and carry a risk of transferring medication through skin contact. Injections require secure storage, consistent scheduling, and access to trained personnel. Interrupted supplies could cause fluctuating hormone levels and recurring symptoms.
The Pentagon must determine whether troops receiving treatment will remain deployable, how medication will be distributed in austere environments, and what happens when laboratory monitoring is unavailable.
These details may ultimately decide whether the program improves readiness or creates a new category of medical limitations.
Women’s Hormone Health Could Become the Policy’s Equality Test
Hegseth referred broadly to troops, but the Pentagon has not clearly explained how the screening program will apply to women.
Women also produce testosterone, although typical levels and clinical considerations differ substantially. Female service members may experience hormonal conditions that affect bone health, sleep, concentration, and physical performance.
The central issue is not whether military women should receive an identical test. It is whether the Pentagon will invest equally in diagnosing and treating hormone-related conditions that affect their readiness.
The question carries added weight because the department has taken a different approach to other forms of hormone care. In 2025, the Pentagon moved to restrict newly initiated cross-sex hormone treatment for personnel diagnosed with gender dysphoria while directing the separation of many affected service members.
The medical purposes are distinct and should not be conflated. Still, the contrast will intensify debate over which hormone treatments the Pentagon defines as readiness-enhancing and which it considers incompatible with service.
The Real Test Will Come After the Results Arrive
Hegseth’s policy begins with a defensible principle: service members should not be forced to perform demanding duties while a genuine medical condition remains undiagnosed.
But testosterone is not a universal measurement of strength, courage, or combat effectiveness.
Readiness also depends on sleep, nutrition, mental health, injury recovery, leadership, training, and family stability. Hormone treatment may help troops with confirmed hypogonadism, but it cannot repair every source of fatigue or reduced performance.
We should measure the program by more than the number of troops tested or prescriptions issued. The Pentagon should track whether treatment improves documented symptoms, reduces medical limitations, and supports long-term health without increasing unnecessary prescriptions or creating career pressure.
The most important part of Hegseth’s testosterone policy will not be the blood draw. It will be the discipline shown afterward that determines whether doctors must decide whether a low number represents a treatable disorder, a temporary reaction to military life, or a warning that something entirely different is wrong.
